Thompson Peter A.
SEC CIK 1357522 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SION | Sionna Therapeutics, Inc. | Dir | 2.47M | $9.90M | $55.67M | 12 | 2025-02-10 | 2026-07-07 |
| CRVS | Corvus Pharmaceuticals, Inc. | Dir, 10% | 120.0K | — | $11.65M | 4 | 2021-09-20 | 2026-01-28 |
| EWTX | Edgewise Therapeutics, Inc. | Dir, 10% | 443.8K | $20.99M | — | 4 | 2022-05-18 | 2025-04-03 |
| SPRY | ARS Pharmaceuticals, Inc. | Dir | 0 | $3.10M | $12.59M | 3 | 2023-08-29 | 2024-08-26 |
| JANX | Janux Therapeutics, Inc. | Dir | 2.26M | — | $10.59M | 3 | 2021-12-16 | 2021-12-29 |
Most active insiders at SION, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Thompson Peter A. | Dir | — | $55.67M |
| 2 | ORBIMED ADVISORS LLC | Dir | — | $52.73M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | — | $27.34M |
| 4 | Booth Bruce | Dir | — | $22.09M |
| 5 | RA Capital Nexus Fund III, L.P. | Dir | — | $14.76M |
| 6 | WINKELRIED JON | 10% | — | $10.00M |
| 7 | Cloonan Michael | Pres, CEO, Dir | — | $5.13M |
| 8 | OrbiMed Capital GP VIII LLC | Dir | — | $2.95M |
| 9 | Fitzpatrick Jennifer | CLO, Head of Program Mgmt | — | $1.21M |
| 10 | Kolchinsky Peter | Dir, 10% | — | $1.20M |
Transactions 26
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TI | 2026-07-09 16:47 | 2026-07-07 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.86 | -85.9K | 2.47M | -3% | -$3.85M |
| TI | 2026-07-02 16:45 | 2026-06-30 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $45.50 | -115.8K | 2.56M | -4% | -$5.27M |
| TI | 2026-05-29 21:02 | 2026-05-27 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.49 | -101 | 2.67M | -0.0% | -$4,493 |
| MTI | 2026-05-11 19:14 | 2026-05-07+ | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $45.62 | -293.0K | 2.67M | -10% | -$13.36M |
| MTI | 2026-04-21 20:42 | 2026-04-17+ | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.67 | -55.3K | 2.96M | -2% | -$2.47M |
| MTI | 2026-04-16 19:15 | 2026-04-14+ | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.94 | -510.6K | 3.02M | -14% | -$22.95M |
| MI | 2026-02-04 | 2026-02-02+ | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.58 | -31.0K | 3.53M | -0.9% | -$1.38M |
| DM | 2026-01-30 | 2026-01-28 | CRVS | Corvus Pharmaceuticals, Inc. | Thompson Peter A. | Dir, 10% | M - OptEx | $5.33 | +210.0K | 120.0K | New | +$1.12M |
| I | 2025-12-29 | 2025-12-24 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.55 | -33.4K | 3.56M | -0.9% | -$1.49M |
| MI | 2025-12-19 | 2025-12-17+ | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.49 | -1,875 | 3.60M | -0.1% | -$83.4K |
| MI | 2025-11-26 | 2025-11-24+ | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.55 | -108.1K | 3.61M | -3% | -$4.81M |
| DI | 2025-07-01 | 2025-06-27 | CRVS | Corvus Pharmaceuticals, Inc. | Thompson Peter A. | Dir, 10% | X - OptEx | $3.50 | +1.40M | 8.34M | +20% | +$4.89M |
| DI | 2025-07-01 | 2025-06-27 | CRVS | Corvus Pharmaceuticals, Inc. | Thompson Peter A. | Dir, 10% | S - Sale+OE | $4.16 | -1.18M | 7.17M | -14% | -$4.89M |
| MI | 2025-04-04 | 2025-04-03 | EWTX | Edgewise Therapeutics, Inc. | Thompson Peter A. | Dir, 10% | P - Purchase | $20.13 | +496.8K | 443.8K | New | +$10.00M |
| DI | 2025-02-10 | 2025-02-10 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | P - Purchase | $18.00 | +550.0K | 3.70M | +17% | +$9.90M |
| DI | 2025-02-10 | 2025-02-10 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | C - Cnv Deriv | — | +3.15M | 3.15M | New | — |
| I | 2024-08-28 | 2024-08-26 | SPRY | ARS Pharmaceuticals, Inc. | Thompson Peter A. | Dir | S - Sale | $13.00 | -83.7K | 0 | -100% | -$1.09M |
| MI | 2024-08-23 | 2024-08-21+ | SPRY | ARS Pharmaceuticals, Inc. | Thompson Peter A. | Dir | S - Sale | $13.24 | -868.7K | 83.7K | -91% | -$11.50M |
| I | 2024-01-25 | 2024-01-23 | EWTX | Edgewise Therapeutics, Inc. | Thompson Peter A. | Dir, 10% | P - Purchase | $11.00 | +454.5K | 14.44M | +3% | +$5.00M |
| I | 2023-08-31 | 2023-08-29 | SPRY | ARS Pharmaceuticals, Inc. | Thompson Peter A. | Dir | P - Purchase | $6.20 | +500.0K | 8.02M | +7% | +$3.10M |
| I | 2022-09-16 | 2022-09-16 | EWTX | Edgewise Therapeutics, Inc. | Thompson Peter A. | Dir, 10% | P - Purchase | $10.32 | +484.5K | 13.98M | +4% | +$5.00M |
| I | 2022-05-20 | 2022-05-18 | EWTX | Edgewise Therapeutics, Inc. | Thompson Peter A. | Dir, 10% | P - Purchase | $7.21 | +138.0K | 13.50M | +1% | +$995.0K |
| MI | 2021-12-30 | 2021-12-29 | JANX | Janux Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $20.30 | -40.4K | 2.26M | -2% | -$820.1K |
| MI | 2021-12-23 | 2021-12-21 | JANX | Janux Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $19.00 | -119.4K | 234.8K | -34% | -$2.27M |
| MI | 2021-12-17 | 2021-12-16 | JANX | Janux Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $19.07 | -393.3K | 2.40M | -14% | -$7.50M |
| I | 2021-09-22 | 2021-09-20 | CRVS | Corvus Pharmaceuticals, Inc. | Thompson Peter A. | Dir, 10% | S - Sale | $6.09 | -1.11M | 6.94M | -14% | -$6.76M |
Purchase Sale Sale after option exercise All abbreviations